{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:00:01Z","timestamp":1786636801110,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/2230-8210.94257","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T08:36:29Z","timestamp":1332578189000},"page":"41","source":"Crossref","is-referenced-by-count":8,"title":["Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin"],"prefix":"10.4103","volume":"16","author":[{"given":"ReshamR","family":"Poudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.94257-1","first-page":"65","volume-title":"Type 1 1\/2 diabetes: Myth or reality?","author":"Juneja","year":"1999","journal-title":"Autoimmunity"},{"key":"key-10.4103\/2230-8210.94257-2","first-page":"970","volume-title":"A Clinical screening tool identifies autoimmune diabetes in adults","author":"Fourlanos","year":"2006","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-3","first-page":"374","volume-title":"Insulin resistance in latent autoimmune diabetes of adulthood","author":"Behme","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/2230-8210.94257-4","first-page":"4635","volume-title":"Latent autoimmune diabetes in adults","author":"Naik","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.94257-5","first-page":"160","volume-title":"Metabolic syndrome and autoimmune diabetes: Action LADA 3","author":"Hawa","year":"2009","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-6","first-page":"608","volume-title":"Genetic heterogeneity of autoimmune diabetes: Age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43).UK Prospective Diabetes Study (UKPDS) Group","author":"Horton","year":"1999","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.94257-7","first-page":"615","volume-title":"T-cell insulitis found in anti-GAD651+ diabetes with residual function.A case report","author":"Shimada","year":"1999","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-8","first-page":"2569","volume-title":"Elevated C-reactive protein levels in the development of type 1 diabetes","author":"Chase","year":"2004","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.94257-9","first-page":"S16","volume-title":"Five stages of evolving beta-cell dysfunction during progression to diabetes","author":"Weir","year":"2004","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.94257-10","doi-asserted-by":"crossref","unstructured":"Pozzilli P, Visalli N, Buzzetti R, Cavallo MG, Marietti G, Hawa M, et al. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: A population-based study. IMDIAB study group. Immunotherapy diabetes. Metabolism 1998;47:1205-10.","DOI":"10.1016\/S0026-0495(98)90324-9"},{"key":"key-10.4103\/2230-8210.94257-11","first-page":"539","volume-title":"Definition, diagnosis and classification of diabetes mellitus and its complications.Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"key-10.4103\/2230-8210.94257-12","first-page":"359","volume-title":"Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease","author":"Tuomi","year":"1993","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.94257-13","first-page":"25","volume-title":"Clinical applications of diabetes antibody testing","author":"Bingley","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.94257-14","first-page":"1288","volume-title":"UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes: UK Prospective Diabetes Study Group","author":"Turner","year":"1997","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.94257-15","first-page":"561","volume-title":"Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus","author":"Landin-Olsson","year":"1990","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.94257-16","first-page":"246","volume-title":"B-Cell protection and therapy for latent autoimmune diabetes in adults","author":"Cernea","year":"2009","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-17","first-page":"2206","volume-title":"Latent autoimmune diabetes in adults (LADA) should be less latent","author":"Fourlanos","year":"2005","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.94257-18","first-page":"150","volume-title":"Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies","author":"Tuomi","year":"1999","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.94257-19","first-page":"439","volume-title":"Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults","author":"Brophy","year":"2008","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-20","first-page":"119","volume-title":"Diabetes-related antibodies in adult diabetic patients","author":"Falorni","year":"2005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.94257-21","first-page":"820","volume-title":"Prevalence of type 1 diabetes autoantibodies (GADA, IA2,and IAA) in overweight and obese children","author":"Cambuli","year":"2010","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-22","first-page":"61","volume-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","author":"Sacks","year":"2011","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-23","first-page":"250","volume-title":"C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve B-cell function report of an ADA workshop, 21-22 October 2001","author":"Palmer","year":"2004","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.94257-24","doi-asserted-by":"crossref","unstructured":"The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-6.","DOI":"10.1210\/jcem-65-1-30"},{"key":"key-10.4103\/2230-8210.94257-25","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized controlled trial. Ann Intern Med 1998;128:517-23.","DOI":"10.7326\/0003-4819-128-7-199804010-00001"},{"key":"key-10.4103\/2230-8210.94257-26","first-page":"1207","volume-title":"Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment","author":"Karges","year":"2004","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-27","first-page":"1210","volume-title":"Clinical review: Type 1 diabetes-associated autoimmunity: Natural history, genetic associations, and screening","author":"Barker","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.94257-28","first-page":"695","volume-title":"Islet autoantibodies in clinically diagnosed type 2 diabetes: Prevalence and relationship with metabolic control (UKPDS 70)","author":"Davis","year":"2005","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.94257-29","first-page":"1460","volume-title":"Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult) definition, characterization, and potential prevention","author":"Pozzilli","year":"2001","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.94257-30","first-page":"827","volume-title":"The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal.Scandinavian Insulin-Sulphonylurea Study Group Research Team","author":"Landstedt-Hallin","year":"1999","journal-title":"Diabet Med"},{"key":"key-10.4103\/2230-8210.94257-31","first-page":"763","volume-title":"Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth","author":"Holloway","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.94257-32","first-page":"203","volume-title":"Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA)","author":"Zhou","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"key-10.4103\/2230-8210.94257-33","first-page":"959","volume-title":"Insulin suppresses its own secretion in vivo","author":"Argoud","year":"1987","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.94257-34","first-page":"289","volume-title":"Isohormonal therapy of endocrine autoimmunity","author":"Schloot","year":"1995","journal-title":"Immunol Today"},{"key":"key-10.4103\/2230-8210.94257-35","first-page":"2115","volume-title":"Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus","author":"Maruyama","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.94257-36","first-page":"239","volume-title":"b-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: A 3-year follow-up","author":"Thunander","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"key-10.4103\/2230-8210.94257-37","first-page":"1749","volume-title":"Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (diaPep277): A randomised, double blind, phase II trial","author":"Raz","year":"2001","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.94257-38","first-page":"238","volume-title":"Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes","author":"Agardh","year":"2005","journal-title":"J Diabetes Complications"},{"key":"key-10.4103\/2230-8210.94257-39","first-page":"1692","volume-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.94257-40","first-page":"2598","volume-title":"Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes","author":"Keymeulen","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:01:12Z","timestamp":1786633272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2230-8210.94257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"alternative-id":["94257"],"URL":"https:\/\/doi.org\/10.4103\/2230-8210.94257","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}